CHMP recommends extended approval for Menveo(Novartis)for Meningococcal Disease

The CHMP recommends approval for an extended indication of Menveo (meningococcal vaccine) from Novartis which protects against Neisseria meningitidis groups A, C, W135 and Y,and will shortly be indicated for use in children aged two years and older, as well as adolescents and adults at risk of exposure to the bacteria, to prevent invasive disease. It is currently approved for use in adolescents (11 years and older) and adults. The final EU approval will bring the label into line with that in the USA where it has been approved since 2010 for patients between two and 55 years.